HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, Aug. 26, 2022 (HealthDay News) -- The U.S. Food and Drug Administration has approved Imbruvica (ibrutinib) for pediatric patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
The approval was based on a trial of 47 patients (age range, 1 to 19 years; 70 percent male) with moderate or severe cGVHD. At week 25, the overall response rate was 60 percent, with a median duration of response of 5.3 months. From first response to death or new systemic therapies for cGVHD, the median time was 14.8 months. Anemia, musculoskeletal pain, pyrexia, diarrhea, pneumonia, abdominal pain, stomatitis, thrombocytopenia, and headache were the most common adverse reactions reported (≥20 percent).
The FDA recommends an oral dosage of 420 mg of Imbruvica once a day for patients aged 12 years and older with cGVHD and 240 mg/m2 orally once daily (up to a dose of 420 mg) for patients aged 1 year to younger than 12 years with cGVHD, until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. Formulations include capsules, tablets, and an oral suspension.
Applications for this approval were granted priority review, and Imbruvica was granted orphan drug designation. Approval of Imbruvica was granted to Pharmacyclics.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on September 21, 2022